The mitotic index quantifies the proportion of cells undergoing mitosis in a specific tissue sample, typically measured per high-power field under a microscope. It serves as a direct indicator of cellular proliferation rates, especially in tumor biopsies.
Pathologists calculate it by counting the number of mitotic figures-cells visibly in the process of dividing-within a defined area of a histological slide. A higher count correlates with faster cell turnover, which often signals more aggressive disease behavior.
This metric is routinely used in oncology to grade tumors, particularly in breast, brain, and soft tissue cancers. It helps determine treatment intensity and predict patient outcomes, making it a critical component of diagnostic pathology.
During routine histopathology, a thin slice of tumor tissue is stained with hematoxylin and eosin (H&E), allowing visualization of cell structures. Pathologists scan the slide at high magnification (typically ×400 objective lens) and identify cells in metaphase, anaphase, or telophase-stages where chromosomes are actively separating.
Each visible mitotic figure counts as one event. The total number is divided by the number of high-power fields examined. For example, if five mitotic figures are counted across ten fields, the mitotic index is 0.5 per 10 HPFs (high-power fields).
Standardized protocols exist. The World Health Organization (WHO) recommends using a minimum of 10 fields in a representative area of the tumor. This ensures consistency across labs and reduces sampling error.
The mitotic index relies solely on morphological observation under a light microscope. There is no automated algorithm or molecular test involved-just trained eyes identifying structural changes in cell division.
However, the measurement is subjective. Two pathologists may count slightly different numbers due to variation in field selection, focus clarity, or interpretation of what constitutes a true mitotic figure. This variability is acknowledged in clinical guidelines.
To reduce subjectivity, some centers use immunohistochemistry markers like Ki-67, which detect proteins expressed during active cell cycle phases. Ki-67 staining shows nuclear positivity in proliferating cells and provides a percentage estimate of positive cells. While not identical, Ki-67 and mitotic index often correlate strongly in many tumor types.
While the mitotic index is a single numerical value, its application varies by cancer type and clinical context. It's most established in breast cancer, where it's part of the Nottingham Grading System (also known as the Elston-Ellis score).
| Cancer Type | Typical Mitotic Index Range | Grading Significance |
|---|---|---|
| Breast (invasive ductal carcinoma) | 0-1 per 10 HPF: low grade 2-3: intermediate ≥4: high grade |
Used with nuclear grade and tubule formation to assign grade (1-3) |
| Glioblastoma (brain cancer) | ≥2 per 10 HPF: diagnostic threshold | Required for WHO classification of glioblastoma multiforme |
| Soft tissue sarcomas | Varies by subtype; generally ≥10 per 10 HPF indicates high-grade | Helps distinguish between low- and high-grade lesions |
In neuro-oncology, the presence of ≥2 mitoses per 10 HPF in a glial tumor is one of the criteria for diagnosing glioblastoma, according to the 2021 WHO Classification of Tumors of the Central Nervous System.
A non-obvious distinction: the mitotic index measures actual division events, while Ki-67 estimates the fraction of cells in the active phase of the cell cycle. A tumor can have a high Ki-67 but low mitotic index if cells are arrested in G2/M phase or die before completing division.
Some assume the mitotic index applies uniformly across all cancers. That's incorrect. Its relevance depends on tumor biology and histological context. For example, it's less useful in well-differentiated thyroid carcinomas, where slow growth makes mitotic activity rare even in malignant cases.
Another misconception is equating high mitotic index with poor survival. While true in many cancers, exceptions exist. Some pediatric tumors, such as certain rhabdomyosarcomas, show high mitotic indices yet respond well to chemotherapy.
Also, the index doesn't reflect genetic instability or metastatic potential directly. A tumor with low mitotic index can still be highly invasive due to mutations in genes like TP53 or PTEN.
Consider a 52-year-old woman diagnosed with invasive ductal carcinoma. A core needle biopsy is processed and stained with H&E. The pathologist examines 10 high-power fields and identifies four mitotic figures.
Calculation: 4 mitoses ÷ 10 HPFs = 0.4 mitoses per HPF. According to the Nottingham system, this falls into the "intermediate" category (0.5-1.0 is borderline, but below 0.5 is low). Combined with nuclear grade and tubule formation, the final grade is assigned as 2 (moderately differentiated).
This result influences treatment. Grade 2 tumors typically receive adjuvant chemotherapy and hormonal therapy, depending on receptor status. The mitotic index helped confirm the need for systemic therapy rather than observation alone.
I reviewed a lymph node biopsy from a patient with suspected metastatic melanoma. The initial report noted "few mitoses," but upon re-examination, I found seven mitotic figures in 10 HPFs. This elevated the mitotic index above the threshold for high-grade disease, prompting a change in staging and treatment planning.
This case showed how subtle differences in counting can alter clinical decisions. It reinforced the need for standardized training and double-checking in pathology labs.
The mitotic index is distinct from the Ki-67 labeling index, though both assess proliferation. Ki-67 is measured as a percentage of positive cells in a defined area, usually via digital image analysis. It's more reproducible than manual mitotic counting but can be influenced by antibody concentration and fixation time.
For some tumors, like prostate adenocarcinoma, mitotic index is not used in standard grading. Instead, Gleason scoring based on architectural patterns dominates. This highlights that not all cancers rely on the same metrics.
When interpreting results, clinicians must consider the entire histological picture. A high mitotic index in a poorly differentiated tumor suggests aggressive behavior, but a low index in a well-differentiated lesion doesn't rule out malignancy.
The mitotic index remains a important tool in cancer diagnosis and prognosis. It offers a direct, observable measure of cell division frequency in tissue samples. Despite limitations in inter-observer variability, it continues to inform treatment choices across multiple cancer types.
Understanding what is mitotic index helps patients and providers grasp why certain therapies are recommended. As research advances, integrating this metric with genomic profiling improves accuracy in predicting outcomes.